909561-15-5
909561-15-5 structure
- Name: AS1810722
- Chemical Name: AS1810722
- CAS Number: 909561-15-5
- Molecular Formula: C25H25F2N7O
- Molecular Weight: 477.51
- Catalog: Signaling Pathways JAK/STAT Signaling STAT
- Create Date: 2021-08-28 12:10:57
- Modify Date: 2024-01-14 11:40:37
-
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research[1].
| Name | AS1810722 |
|---|
| Description | AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research[1]. |
|---|---|
| Related Catalog | |
| Target |
STAT6:1.9 nM (IC50) CYP3A4 |
| In Vitro | AS1810722 (compound 24) inhibits production of IL-4 with an IC50 of 2.4 nM, but shows no effect on production of IFN-γ[1]. |
| In Vivo | AS1810722 (compound 24; 0.03-0.3 mg/kg; orally; 30 min before, and 24h and 48 h after OVA exposure) suppress eosinophil infiltration in the lung in a dose-dependent manner in an antigen-induced mouse asthmatic model[1]. AS1810722 inhibits in vitro Th2 differentiation with an IC50 of 2.4 nM without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration[1]. Animal Model: Female Balb/c mice asthmatic model by intraperitoneal injection of ovalbumin (OVA)-containing aluminum hydroxide gel[1] Dosage: 0.03-0.3 mg/kg Administration: Orally; 30 min before, and 24 and 48 h after OVA exposure Result: Suppressed eosinophil infiltration in the lung in a dose-dependent manner. |
| References |
| Molecular Formula | C25H25F2N7O |
|---|---|
| Molecular Weight | 477.51 |
| Hazard Codes | Xi |
|---|